Keywords: negative, press, compromised, vytorin, first-line, therapy, dr

Negative press has compromised Vytorin as first-line therapy; DR

Article | 17 November 2008

Print This

Merck & Co/Schering-Plough\'s promotion of Vytorin (ezetimibe and simvastatin) as a first-line agent in the treatment of dyslipidemia has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in